RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

PHASE1CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

March 31, 2014

Conditions
Respiratory Syncytial Virus (RSV)
Interventions
BIOLOGICAL

Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)

0.5mL IM injections

BIOLOGICAL

Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)

0.5mL IM injections

BIOLOGICAL

High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)

0.5mL IM injections

BIOLOGICAL

High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)

0.5mL IM injections

BIOLOGICAL

Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)

0.5mL IM Injections

Trial Locations (4)

32935

Accelovance, Melbourne

75234

Research Across America, Dallas

84124

Jean Brown Research, Salt Lake City

85704

Genova Clinical Research, Tucson

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novavax

INDUSTRY